SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Celgene International Sárl Release: REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment for Patients with Treatment-Naive Chronic Lymphocytic Leukemia